A colorless explosive liquid that is volatile and poisonous and foul-smelling.
1Conclusion: Early enteral feeding with FOSL-HN was safe and well tolerated.
2The HN catheter appeared to be associated with lower TEI-SAE, versus other catheters.
3Participants completed the MD Anderson Symptom Inventory-Head and Neck module (MDASI-HN).
4Vaccination of Lewis rats with naked DNA encoding these pathogenic TCRs significantly protected against HN.
5Several amino acid mutations were identified in the functional domains of the F and HN proteins.
6The data strongly suggest improved liver and renal function during the postoperative period in the FOSL-HN group.
7Additional clinical trials to fully quantify clinical benefits and optimize nutritional support with FOSL-HN should be undertaken.
8Participants were classified as having HN-positive or HN-negative findings according to the presence of HNs at baseline physical examination.
9The F protein was the major individual contributor and was sometimes augmented by the homologous M and HN proteins.
10The 10-year cumulative risk for HN and esophageal carcinoma was 2.59%.
11The immune response ability of HN in the APP-infected pigs was weakened; however, cell proliferation and migration ability was enhanced.
12Cotton rats inoculated with recombinant MVA expressing F or HN by intramuscular or intranasal routes produced high levels of antibody.
13This study quantified the risk of head and neck (HN) and esophageal cancers in 2770 Italian liver transplant (LT) recipients.
14Results showed that the full-length genomes of this isolate were 15,198 nucleotides with the gene order of 3'-NP-P-M-F-HN-L-5'.
15The purpose of this study is to evaluate the role of this new technology in the management of previously untreated HN cancer patients.
16A few retrospective studies have been performed, but adequate sample sizes are lacking because the number of HN cancer patients is relatively small.